JP2011520810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520810A5 JP2011520810A5 JP2011508593A JP2011508593A JP2011520810A5 JP 2011520810 A5 JP2011520810 A5 JP 2011520810A5 JP 2011508593 A JP2011508593 A JP 2011508593A JP 2011508593 A JP2011508593 A JP 2011508593A JP 2011520810 A5 JP2011520810 A5 JP 2011520810A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- cycloalkyl
- substituted
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 69
- -1 pyridinonyl Chemical group 0.000 claims 42
- 239000001257 hydrogen Substances 0.000 claims 33
- 229910052739 hydrogen Inorganic materials 0.000 claims 33
- 125000000753 cycloalkyl group Chemical group 0.000 claims 28
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 21
- HJHICYAWGPPIND-UHFFFAOYSA-N 7h-indolo[2,1-a][2]benzazepine-10-carboxamide Chemical compound C1=CCN2C3=CC(C(=O)N)=CC=C3C=C2C2=CC=CC=C21 HJHICYAWGPPIND-UHFFFAOYSA-N 0.000 claims 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 17
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 17
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 14
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 125000004663 dialkyl amino group Chemical group 0.000 claims 12
- 125000003386 piperidinyl group Chemical group 0.000 claims 10
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 10
- 125000004193 piperazinyl group Chemical group 0.000 claims 9
- 125000004103 aminoalkyl group Chemical group 0.000 claims 8
- 125000002757 morpholinyl group Chemical group 0.000 claims 8
- 125000002393 azetidinyl group Chemical group 0.000 claims 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 229940121649 protein inhibitor Drugs 0.000 claims 6
- 239000012268 protein inhibitor Substances 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 229940122750 HCV entry inhibitor Drugs 0.000 claims 2
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims 2
- 229940121759 Helicase inhibitor Drugs 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 2
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 2
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims 2
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 239000003001 serine protease inhibitor Substances 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 0 *C1(*2)C2c(cccc2)c2-c2c(*)c(ccc(*)c3)c3[n]2C1 Chemical compound *C1(*2)C2c(cccc2)c2-c2c(*)c(ccc(*)c3)c3[n]2C1 0.000 description 66
- LLAMAEIOZLEXMF-UHFFFAOYSA-N CN1C(CC2)CC2C1 Chemical compound CN1C(CC2)CC2C1 LLAMAEIOZLEXMF-UHFFFAOYSA-N 0.000 description 4
- AWZLXVAPLHUDSY-UHFFFAOYSA-N CCC1N(C)CCNC1 Chemical compound CCC1N(C)CCNC1 AWZLXVAPLHUDSY-UHFFFAOYSA-N 0.000 description 3
- NXRVZBNEFIJNLH-UHFFFAOYSA-N CN(CC(C1)C2=CC=C3)CC1[IH]N2C3=O Chemical compound CN(CC(C1)C2=CC=C3)CC1[IH]N2C3=O NXRVZBNEFIJNLH-UHFFFAOYSA-N 0.000 description 3
- JMGQDYJFBQGUDC-UHFFFAOYSA-N CN1C(C2)COC2C1 Chemical compound CN1C(C2)COC2C1 JMGQDYJFBQGUDC-UHFFFAOYSA-N 0.000 description 3
- VYLGWVNPNMMXFQ-UHFFFAOYSA-N CN1C(CC2)CCN2CC1 Chemical compound CN1C(CC2)CCN2CC1 VYLGWVNPNMMXFQ-UHFFFAOYSA-N 0.000 description 2
- CAFWHFDCQORFGP-UHFFFAOYSA-N CN1C2CCC1CC2 Chemical compound CN1C2CCC1CC2 CAFWHFDCQORFGP-UHFFFAOYSA-N 0.000 description 2
- DIQOUXNTSMWQSA-UHFFFAOYSA-O C1C2[OH+]CC1NC2 Chemical compound C1C2[OH+]CC1NC2 DIQOUXNTSMWQSA-UHFFFAOYSA-O 0.000 description 1
- ODPZNUCDUSZQPY-UHFFFAOYSA-N C=CN1C2COCC1CC2 Chemical compound C=CN1C2COCC1CC2 ODPZNUCDUSZQPY-UHFFFAOYSA-N 0.000 description 1
- UFWHTJSLTADBQW-UHFFFAOYSA-N CC(C1)(CN(C)[IH]C1(C)C1)CN1I Chemical compound CC(C1)(CN(C)[IH]C1(C)C1)CN1I UFWHTJSLTADBQW-UHFFFAOYSA-N 0.000 description 1
- IHHPUXJKPWXNQZ-UHFFFAOYSA-N CCC(CNCC1)N1N Chemical compound CCC(CNCC1)N1N IHHPUXJKPWXNQZ-UHFFFAOYSA-N 0.000 description 1
- DJENJFDIIGLVMM-UHFFFAOYSA-N CCC1N(C)C(CC=O)CC1 Chemical compound CCC1N(C)C(CC=O)CC1 DJENJFDIIGLVMM-UHFFFAOYSA-N 0.000 description 1
- PKKSLYCYJFNJGH-UHFFFAOYSA-N CCC1N(C)CC(C)C1 Chemical compound CCC1N(C)CC(C)C1 PKKSLYCYJFNJGH-UHFFFAOYSA-N 0.000 description 1
- DCIMLHHFMXLZES-UHFFFAOYSA-N CN(C(CC1)C2)C1CN2I Chemical compound CN(C(CC1)C2)C1CN2I DCIMLHHFMXLZES-UHFFFAOYSA-N 0.000 description 1
- GFXFZLNSGUECQD-UHFFFAOYSA-N CN(CC1CC2)C2N1I Chemical compound CN(CC1CC2)C2N1I GFXFZLNSGUECQD-UHFFFAOYSA-N 0.000 description 1
- RQHPJNUMHOOWMZ-UHFFFAOYSA-N CN1C(C2)C2CC1 Chemical compound CN1C(C2)C2CC1 RQHPJNUMHOOWMZ-UHFFFAOYSA-N 0.000 description 1
- GXIMUJOQZCMEFY-UHFFFAOYSA-O CN1C(CC2)C[NH2+]C2C1 Chemical compound CN1C(CC2)C[NH2+]C2C1 GXIMUJOQZCMEFY-UHFFFAOYSA-O 0.000 description 1
- SIELEMMHCJBTLV-UHFFFAOYSA-N C[IH]N1C2CCC1CC2 Chemical compound C[IH]N1C2CCC1CC2 SIELEMMHCJBTLV-UHFFFAOYSA-N 0.000 description 1
- FSOISJCZZXKQAV-UHFFFAOYSA-N IN1C(CC2)CC2C1 Chemical compound IN1C(CC2)CC2C1 FSOISJCZZXKQAV-UHFFFAOYSA-N 0.000 description 1
- OWHLMUQEBRGQON-UHFFFAOYSA-N IN1C2CCC1CC2 Chemical compound IN1C2CCC1CC2 OWHLMUQEBRGQON-UHFFFAOYSA-N 0.000 description 1
- BWMCODNKYUDVEG-UHFFFAOYSA-N IN1C2CCCC1CC2 Chemical compound IN1C2CCCC1CC2 BWMCODNKYUDVEG-UHFFFAOYSA-N 0.000 description 1
- LRGPYKQCGYWQHF-UHFFFAOYSA-N IN1CC(CC2)OC2C1 Chemical compound IN1CC(CC2)OC2C1 LRGPYKQCGYWQHF-UHFFFAOYSA-N 0.000 description 1
- KOOYRAIODCPBIW-UHFFFAOYSA-N IN1CC(CCC2)N2CC1 Chemical compound IN1CC(CCC2)N2CC1 KOOYRAIODCPBIW-UHFFFAOYSA-N 0.000 description 1
- ZQLGQUDAFSYVQU-UHFFFAOYSA-N NN1C(C2)C2CC1 Chemical compound NN1C(C2)C2CC1 ZQLGQUDAFSYVQU-UHFFFAOYSA-N 0.000 description 1
- XHLWXJSWFVJXOB-UHFFFAOYSA-N NN1C(CC2)CCN2CC1 Chemical compound NN1C(CC2)CCN2CC1 XHLWXJSWFVJXOB-UHFFFAOYSA-N 0.000 description 1
- PVZPUMMARUPBLY-UHFFFAOYSA-N NN1CC(CC2)OC2C1 Chemical compound NN1CC(CC2)OC2C1 PVZPUMMARUPBLY-UHFFFAOYSA-N 0.000 description 1
- CVDLBKMNONQOHJ-UHFFFAOYSA-N O=C1CC(CC2)NC2C1 Chemical compound O=C1CC(CC2)NC2C1 CVDLBKMNONQOHJ-UHFFFAOYSA-N 0.000 description 1
- FDBATLOUQOHVKJ-UHFFFAOYSA-N [Tc]N1C(CC2)CNC2C1 Chemical compound [Tc]N1C(CC2)CNC2C1 FDBATLOUQOHVKJ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5074308P | 2008-05-06 | 2008-05-06 | |
| US61/050,743 | 2008-05-06 | ||
| PCT/US2009/042805 WO2009137454A1 (en) | 2008-05-06 | 2009-05-05 | 7h-indolo[2,1-a] [2] benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011520810A JP2011520810A (ja) | 2011-07-21 |
| JP2011520810A5 true JP2011520810A5 (enExample) | 2012-06-21 |
Family
ID=40786514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011508593A Withdrawn JP2011520810A (ja) | 2008-05-06 | 2009-05-05 | Ｃ型肝炎の治療のための７ｈ−インドロ［２，１−ａ］［２］ベンゾアゼピン−１０−カルボン酸誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8133884B2 (enExample) |
| EP (1) | EP2280975B1 (enExample) |
| JP (1) | JP2011520810A (enExample) |
| KR (1) | KR20110015588A (enExample) |
| CN (1) | CN102083834A (enExample) |
| AR (1) | AR071684A1 (enExample) |
| AU (1) | AU2009244409A1 (enExample) |
| BR (1) | BRPI0915130A2 (enExample) |
| CA (1) | CA2723683A1 (enExample) |
| CL (1) | CL2009001089A1 (enExample) |
| CO (1) | CO6290645A2 (enExample) |
| EA (1) | EA201001748A1 (enExample) |
| IL (1) | IL208753A0 (enExample) |
| MX (1) | MX2010011921A (enExample) |
| NZ (1) | NZ588556A (enExample) |
| PE (1) | PE20091879A1 (enExample) |
| TW (1) | TW200951135A (enExample) |
| WO (1) | WO2009137454A1 (enExample) |
| ZA (1) | ZA201007649B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| KR20100124848A (ko) | 2008-03-27 | 2010-11-29 | 브리스톨-마이어스 스큅 컴퍼니 | 방향족 헤테로시클릭 융합된 인돌로벤자디아제핀 ｈｃｖ ｎｓ5ｂ 억제제 |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| CA2822357A1 (en) | 2010-12-22 | 2012-06-28 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| AU2013217224B2 (en) | 2012-02-10 | 2017-04-06 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| US9556204B2 (en) * | 2012-07-18 | 2017-01-31 | Bristol-Myers Squibb Company | Methods and intermediates for the preparation of (4bS,5aR)-12-cyclohexyl-N-(N,N-dimethylsulfamoyl)-3-methoxy-5a-((1R,5S)-3-methyl-3,8-diazabicyclo [3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-A]indole-9-carboxamide |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1719773B1 (en) | 2004-02-24 | 2009-04-15 | Japan Tobacco, Inc. | Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| AU2005298412B2 (en) | 2004-10-26 | 2011-06-09 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| ATE469155T1 (de) | 2006-05-25 | 2010-06-15 | Bristol Myers Squibb Co | Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer |
| WO2007140200A2 (en) | 2006-05-25 | 2007-12-06 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| US7452876B2 (en) | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7541351B2 (en) | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7517872B2 (en) | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7521444B2 (en) | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7547690B2 (en) | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7538102B2 (en) | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7541353B2 (en) | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7538103B2 (en) | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US20090018163A1 (en) | 2007-07-11 | 2009-01-15 | Bristol-Myers Squibb Company | Substituted Heterocyclic Ethers and Their Use in CNS Disorders |
| US7642251B2 (en) | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7652004B2 (en) | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8129367B2 (en) | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
-
2009
- 2009-05-04 US US12/434,748 patent/US8133884B2/en active Active
- 2009-05-05 MX MX2010011921A patent/MX2010011921A/es active IP Right Grant
- 2009-05-05 CA CA2723683A patent/CA2723683A1/en not_active Abandoned
- 2009-05-05 BR BRPI0915130A patent/BRPI0915130A2/pt not_active IP Right Cessation
- 2009-05-05 EA EA201001748A patent/EA201001748A1/ru unknown
- 2009-05-05 NZ NZ588556A patent/NZ588556A/en not_active IP Right Cessation
- 2009-05-05 AU AU2009244409A patent/AU2009244409A1/en not_active Abandoned
- 2009-05-05 PE PE2009000605A patent/PE20091879A1/es not_active Application Discontinuation
- 2009-05-05 WO PCT/US2009/042805 patent/WO2009137454A1/en not_active Ceased
- 2009-05-05 KR KR1020107027222A patent/KR20110015588A/ko not_active Withdrawn
- 2009-05-05 CN CN2009801263266A patent/CN102083834A/zh active Pending
- 2009-05-05 JP JP2011508593A patent/JP2011520810A/ja not_active Withdrawn
- 2009-05-05 EP EP09743440.1A patent/EP2280975B1/en not_active Ceased
- 2009-05-06 AR ARP090101641A patent/AR071684A1/es not_active Application Discontinuation
- 2009-05-06 TW TW098115001A patent/TW200951135A/zh unknown
- 2009-05-06 CL CL2009001089A patent/CL2009001089A1/es unknown
-
2010
- 2010-10-14 IL IL208753A patent/IL208753A0/en unknown
- 2010-10-26 ZA ZA2010/07649A patent/ZA201007649B/en unknown
- 2010-10-28 CO CO10134256A patent/CO6290645A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011520810A5 (enExample) | ||
| JP2010521483A5 (enExample) | ||
| JP2010521476A5 (enExample) | ||
| JP2010521481A5 (enExample) | ||
| JP2010515752A5 (enExample) | ||
| JP2010521484A5 (enExample) | ||
| JP2008530096A5 (enExample) | ||
| JP2010510234A5 (enExample) | ||
| US8426458B2 (en) | Hepatitis C Virus inhibitors | |
| JP2012504632A5 (enExample) | ||
| JP2010535787A5 (enExample) | ||
| JP2011523651A5 (enExample) | ||
| US8420686B2 (en) | Linked diimidazole antivirals | |
| US8609648B2 (en) | Hepatitis C virus inhibitors | |
| ES2449540T3 (es) | Inhibidores macrocíclicos del virus de la hepatitis C | |
| ES2456617T3 (es) | Inhibidores macrocíclicos del virus de la hepatitis C | |
| HRP20120707T1 (hr) | Spojevi za liječenje hepatitisa c | |
| JP2011521965A5 (enExample) | ||
| JP2012504132A5 (enExample) | ||
| JP2014522809A5 (enExample) | ||
| JP2012528161A5 (enExample) | ||
| JP2012519173A5 (enExample) | ||
| HRP20110194T1 (hr) | Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b | |
| WO2007120595A2 (en) | Amines for the treatment of hcv | |
| JP2013514359A5 (enExample) |